Keywords: Bayer, Johnnson & Johnson, Xarelto, Acute coronary syndrome, Survival, ACS

Bayer and J&J's Xarelto aids survival after heart attack

Article | 27 August 2012

Print This

A major subgroup analysis from the ATLAS ACS 2-TIMI 51 study of 7,817 patients with acute coronary syndrome (ACS) and a recent ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in